United States - English - NLM (National Library of Medicine)

henry schein, inc. - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate injection, usp, is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest. none. 8.1 pregnancy animal reproduction studies have not been conducted with atropine. it also is not known whether atropine can cause fetal harm when given to a pregnant woman or can affect reproduction capacity. 8.3 nursing mothers trace amounts of atropine was found in breast milk. the clinical impact of this is not known. 8.5 geriatric use an evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

United States - English - NLM (National Library of Medicine)

henry schein, inc. - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus, carbamate, or muscarinic mushroom poisoning, and to treat symptomatic bradycardia. none. 8.1 pregnancy risk summary limited available data with atropine sulfate injection use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes (see data). there are risks to the mother and fetus associated with untreated severe or life-threatening muscarinic events (see clinical considerations). animal reproduction studies have not been conducted with atropine sulfate injection. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pr

United States - English - NLM (National Library of Medicine)

medefil, inc. - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate injection, usp, is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest. these highlights do not include all the information needed to use atropine sulfate injection safely and effectively. see full prescribing information for atropine sulfate injection. atropine sulfate injection, for intravenous use initial u.s. approval: 1960 none. 8.1 pregnancy animal reproduction studies have not been conducted with atropine. it also is not known whether atropine can cause fetal harm when given to a pregnant woman or can affect reproduction capacity. 8.3 nursing mothers trace amounts of atropine was found in breast milk. the clinical impact of this is not known. 8.4 pediatric use recommendations for use in pediatric patients are not based on clinical trials. 8.5 geriatric use an evaluation of current literature revealed

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratoire aguettant - atropine sulfate monohydrate - solution for injection in pre-filled syringe - 0.1 milligram(s)/millilitre - belladonna alkaloids, tertiary amines; atropine - belladonna alkaloids, tertiary amines - atropine sulfate aguettant 0.1 mg/ml, solution for injection in pre-filled syringe is indicated in adults and in paediatric population from birth, but with a body weight superior to 3 kg - as a pre-anaesthetic medication to prevent vagal reactions associated with tracheal intubation and surgical manipulation, - to limit the muscarinic effects of neostigmine, when given postsurgically to counteract non-depolarising muscle relaxants - treatment of hemodynamically compromising bradycardia and/ or atrioventricular block due to excessive vagal tone in emergency situation - cardiopulmonary resuscitation: to treat symptomatic bradycardia and av block - as antidote following overdosage or poisoning with acetylcholinesterase-inhibitors e.g. anticholinesterases, organophosphorus, carbamates and muscarinic mushrooms

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - atropine sulfate 0.06%{relative} - solution for injection - 600 mcg/ml - active: atropine sulfate 0.06%{relative} excipient: sodium chloride - atropine may be given as a pre-anaesthetic medication to inhibit excessive salivary and bronchial secretions and to diminish the risk of vagal inhibition of the heart. the use of atropine as an antisialagogue is rarely necessary since the introduction of halothane and similar anaesthetics in place of ether anaesthesia. atropine may be administered concurrently with anticholinesterase agents (e.g. neostigmine, physostigmine) to block the adverse muscarinic effects when they are used after surgery to terminate curarisation. it is also used concomitantly with a cholinesterase reactivator (e.g. pralidoxime) to reverse muscarinic effects associated with toxic exposure to anticholinesterase compounds (e.g. organophosphate pesticides). atropine may be used in conjunction with morphine or other agents for the relief of biliary or renal colic. it may be used in the management of patients with acute myocardial infarction and sinus bradycardia who have associated hypotension and increased ventricular irritability.

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pharmaceutical solution industries (psi), saudi arabia - atropine sulfate - solution - 0.6 mg/ml

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pharmaceutical solution industries (psi), saudi arabia - atropine sulfate - solution - 0.6 mg/ml

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pharmaceutical solution industries (psi), saudi arabia - atropine sulfate - solution - 0.6 mg/ml

Malta - English - Medicines Authority

mercury pharma international limited 4045 kingswood road, city west business park, co, dublin, ireland - atropine sulfate - solution for injection - atropine sulfate 600 µg/ml - drugs for functional gastrointestinal disorders

Malta - English - Medicines Authority

pinewood laboratories limited ballymacarbry, clonmel, co. tipperary, ireland - atropine sulfate - tablet - atropine sulfate 600 µg - drugs for functional gastrointestinal disorders